Login to Your Account

Provesica successor Ario revives ion channel candidate for cough

By Nuala Moran
Staff Writer

Tuesday, December 31, 2013
LONDON – A phoenix has arisen from the ashes of Provesica Ltd., raising £1.9 million (US$3.1 million) to repurpose the failed company’s only asset, XEN-D0501, as a treatment for chronic cough.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription